Article
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
Alimentary pharmacology & therapeutics - 1 Feb 2017
Buti M, Calleja J L, Lens S, Diago M, Ortega E, Crespo J, Planas R, Romero-Gómez M, Rodríguez F G, Pascasio J M, Fevery B, Kurland D, Corbett C, Kalmeijer R, Jessner W
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and subsequent hepatocellular carcinoma. HCV genotype 4 is found widely in the Middle East, Egypt and Africa, and has also spread into Europe. There are limited data available regarding the use of direct-acting antiviral agents in HCV genotype 4-infected patients with cirrhosis. AIM: To evaluate in the phase III, open-label,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.